Sponsored By

Lilly
Interview with the Innovators

Recent Clinical Trials of Neoadjuvant Immunotherapy in Breast Cancer

This third installment observes data presented at ESMO 2023 on neoadjuvant immunotherapy in breast cancer, with a discussion of the KEYNOTE-522 study, NeoTRIP study, KEYNOTE-756 study, and the EMBER-2 study.

Video Library

Featuring:

Nadia Harbeck, MD, PhD
Director, Breast Cancer
Professor, Conservative Oncology
LMU University Hospital
Munich, Germany

Interview with the Innovators Presents:
Emerging Data in Early Breast Cancer from ESMO 2023

We are pleased to announce the release of our latest Interview with the Innovators video series. This 3-part video series features expert commentary from Dr Nadia Harbeck, MD, PhD, Ludwig-Maximilians-University of Munich. In this video series, Dr Harbeck recaps data on adjuvant treatment for patients with HR+/HER2- early breast cancer, details new data on prognostic factors in breast cancer, and discusses recent trials investigating neoadjuvant immunotherapy.

Related Items

Managing Neuropathy That May Accompany ADC Therapy in Breast Cancer
By Tajuana Bradley, MS, FNP-BC; Abbey J. Kaler, MS, APRN, FNP-C
Video Library
How can clinicians monitor and manage neuropathy in patients with breast cancer receiving ADC therapy? In this video, Tajuana Bradley, MS, FNP-BC, and Abbey J. Kaler, MS, APRN, FNP-C, discuss practical approaches to initial and ongoing assessments, concomitant medication, and patient education on symptoms that should be reported promptly.
Managing Hematologic Toxicities With ADC Therapy in Breast Cancer
By Tajuana Bradley, MS, FNP-BC; Abbey J. Kaler, MS, APRN, FNP-C
Video Library
How can clinicians monitor and manage hematologic toxicities in patients with breast cancer receiving ADC therapy? In this video, Tajuana Bradley, MS, FNP-BC, and Abbey J. Kaler, MS, APRN, FNP-C, discuss practical approaches to laboratory monitoring and the assessment and management of neutropenia, thrombocytopenia, and anemia, including toxicity grading, treatment modifications, and patient education on symptoms that should be reported promptly.
Assessing Patient Risk Before ADC Therapy in Breast Cancer
By Tajuana Bradley, MS, FNP-BC; Abbey J. Kaler, MS, APRN, FNP-C
Video Library
How can early identification of patient-specific risk factors help optimize patient outcomes and proactively manage toxicity with ADC therapy? In this video, Tajuana Bradley, DNP, FNP-BC, AOCNP, and Abbey Kaler, PA-C, discuss approaches to evaluating baseline risk factors, identifying patients who may be at increased risk for key ADC-related toxicities, and implementing monitoring, multidisciplinary care, and patient education strategies at treatment initiation.
Journal of Oncology Navigation & Survivorship
JONS

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
     
    Profession or Role
    Primary Specialty or Disease State
    Country